European Archives - Page 432 of 1108 - European Medical Journal

Pfizer joins GSK in RSV success

Pfizer plans to file for approval for its RSV vaccine for infants by the end of 2022 after achieving positive Phase 3 results.

Pharma insights from the team behind GOLD

Listen to the GOLD team: Helena, Isabel and Jade will discuss key articles, themes and insights from the latest issue of GOLD.

How is pharma improving animal testing – and what do activists think?

The pharmaceutical industry has been trying to refine, reduce and replace animal testing for some time, but animal rights activists argue progress is too incremental.

Pharma's response to Roe v. Wade

The overturning of Roe v. Wade is impacting access to medical abortion, but in what ways is pharma trying to help?

Retracted: Building on a Strong Foundation to Address a New Era to Help Protect Against Pneumococcal Disease

Ramirez noted that more than 100 pneumococcal serotypes have now been identified, which is most likely the result of increased…

NUVAXOVIDᵀᴹ dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) For Individuals 12 Years and Older

Learn about NUVAXOVIDᵀᴹ dispersion for injection COVID-19 vaccine (recombinant, adjuvanted) for individuals 12 Years and older.

Cutaneous Mucormycosis Co-infection in a Patient with COVID-19

A 54-year-old male tested positive in late February on a screening COVID-19 test performed after a family member’s test had become positive. A few weeks later, they presented to the emergency room at a different hospital centre with shortness of breath and fever.

Roundtable: behind the headlines of Inflation Reduction Act

Two US pricing experts dissect the implications of The Inflation Reduction for the pharma industry in this roundtable.

Updates from the European Society for Medical Oncology 2022 Congress

This week, Jonathan Sackier is joined by Arndt Vogel to discuss his role at ESMO and key themes in cancer care from the ESMO Congress.

Cell and gene therapy: a victim of its own success

Landmark science has led to an inundation of new transformative therapies, but is the cell and gene market at the point of saturation?